MicroRNA (miRNA) Complexity in Alzheimer's Disease (AD)

Walter J Lukiw1,2,3,4

  • 1LSU Neuroscience Center, Louisiana State University Health Science Center, New Orleans, LA 70112, USA.

Biology
|June 28, 2023
PubMed

Insights

MicroRNAs (miRNAs) are key regulators of gene expression in Alzheimer's disease (AD). Analyzing miRNA signatures in brain tissue offers insights into AD mechanisms and potential RNA-based therapeutics.

Area of Science:

  • Neurobiology
  • Molecular Genetics
  • Neurodegenerative Disorders

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia.
  • The heterogeneity of AD stems from complex molecular-genetic mechanisms in the brain.
  • MicroRNAs (miRNAs) play a crucial role in regulating gene expression within brain cells.

Purpose of the Study:

  • To analyze miRNA populations in Alzheimer's disease (AD) brains.
  • To characterize miRNA abundance, speciation, and complexity in relation to AD.
  • To identify miRNA-based signatures for understanding AD pathogenesis and developing therapeutics.

Main Methods:

  • Analysis of high-quality post-mortem brain tissues from AD patients and age/gender-matched controls.
  • Characterization of free and exosome-bound miRNA species in the human brain and CNS.
  • Review of current research on miRNA signaling complexity in the hippocampal CA1 region of AD brains.

Main Results:

  • Identification of specific miRNA species significantly affected by the AD process.
  • Determination of pathophysiological miRNA-based signatures in AD brains.
  • Consolidation of findings on abundant and affected miRNA species from multiple research laboratories.

Conclusions:

  • miRNA analysis provides valuable molecular-genetic insights into Alzheimer's disease (AD).
  • Pathophysiological miRNA signatures can enhance mechanistic understanding of AD.
  • Findings support the future development of miRNA- and related RNA-based therapeutics for AD.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
530
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222